NO20050425L - Anvendelse av vasopeptidase inhibitorer ved behandlingen av nefropati - Google Patents

Anvendelse av vasopeptidase inhibitorer ved behandlingen av nefropati

Info

Publication number
NO20050425L
NO20050425L NO20050425A NO20050425A NO20050425L NO 20050425 L NO20050425 L NO 20050425L NO 20050425 A NO20050425 A NO 20050425A NO 20050425 A NO20050425 A NO 20050425A NO 20050425 L NO20050425 L NO 20050425L
Authority
NO
Norway
Prior art keywords
diabetic
nephropathy
treatment
vasopeptidase inhibitors
atherosclerosis
Prior art date
Application number
NO20050425A
Other languages
English (en)
Other versions
NO334811B1 (no
Inventor
Wolfgang Linz
Markus Bleich
Jochen Huber
Stefan Schafer
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of NO20050425L publication Critical patent/NO20050425L/no
Publication of NO334811B1 publication Critical patent/NO334811B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Det er beskrevet anvendelse av vasopeptidase inhibitorer av formel (1) for behandling og/eller profylakse av nefropati i diabetiske eller ikke- diabetiske pasienter, innbefattende diabetisk eller ikke-diabetisk nefropati, glomerulonefiitt, glomerulær sklerose, nefrotisk syndrom, hypertensiv nefrosklerose, mikroalbuminuri eller sluttstadiet nyresykdom, eller insulinresistens eller av metabohske sykdommer forbimdet med avanserte glycerings-sluttprodukter, så som diabetiske komplikasjoner, diabetisk neuropati, diabetisk nefropati, diabetisk retinopati, katarakter, myokardialt infarkt og/eller diabetisk kardiomyopati, eller aterosklerose eller endotelisk dysfiinksjon.
NO20050425A 2002-06-28 2005-01-25 Anvendelse av vasopeptidase-inhibitorer for fremstilling av et medikament for behandling og/eller profylakse av nefropati i diabetiske pasienter. NO334811B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2002129180 DE10229180A1 (de) 2002-06-28 2002-06-28 Verwendung von Vasopeptidase-Inhibitoren bei der Behandlung von metabolischen Erkrankungen, Nephropathie und mit AGE assoziierten Erkrankungen
PCT/EP2003/006276 WO2004002492A1 (en) 2002-06-28 2003-06-13 Use of vasopeptidase inhibitors in the treatment of nephropathy

Publications (2)

Publication Number Publication Date
NO20050425L true NO20050425L (no) 2005-01-25
NO334811B1 NO334811B1 (no) 2014-06-02

Family

ID=29795983

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050425A NO334811B1 (no) 2002-06-28 2005-01-25 Anvendelse av vasopeptidase-inhibitorer for fremstilling av et medikament for behandling og/eller profylakse av nefropati i diabetiske pasienter.

Country Status (39)

Country Link
US (2) US6930103B2 (no)
EP (1) EP1519732B1 (no)
JP (1) JP4564354B2 (no)
KR (1) KR101072235B1 (no)
CN (1) CN100366254C (no)
AR (1) AR040343A1 (no)
AT (1) ATE548040T1 (no)
AU (1) AU2003280440B2 (no)
BR (1) BR0312250A (no)
CA (1) CA2490277C (no)
CR (1) CR7667A (no)
CY (1) CY1112905T1 (no)
DE (1) DE10229180A1 (no)
DK (1) DK1519732T3 (no)
EC (1) ECSP045513A (no)
ES (1) ES2383889T3 (no)
HK (1) HK1079435A1 (no)
HN (1) HN2003000193A (no)
HR (1) HRP20041212B1 (no)
IL (2) IL165935A0 (no)
MA (1) MA27281A1 (no)
MX (1) MXPA04012230A (no)
NO (1) NO334811B1 (no)
NZ (1) NZ537480A (no)
OA (1) OA12871A (no)
PA (1) PA8576501A1 (no)
PE (1) PE20040582A1 (no)
PL (1) PL218070B1 (no)
PT (1) PT1519732E (no)
RS (1) RS52478B (no)
RU (1) RU2336080C2 (no)
SI (1) SI1519732T1 (no)
SV (1) SV2004001560A (no)
TN (1) TNSN04262A1 (no)
TW (1) TWI326215B (no)
UA (1) UA82845C2 (no)
UY (1) UY27869A1 (no)
WO (1) WO2004002492A1 (no)
ZA (1) ZA200409382B (no)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2482546C2 (ru) * 2011-04-28 2013-05-20 Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" Способ коррекции эндотелиальной дисфункции раствором гомеопатических разведений антител к с-концевому фрагменту рецептора ангиотензина ii

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5430145A (en) * 1990-10-18 1995-07-04 Merrell Dow Pharmaceuticals Inc. Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
CA2053340C (en) * 1990-10-18 2002-04-02 Timothy P. Burkholder Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
DE69211133T2 (de) * 1991-03-01 1996-10-31 Zeria Pharmaceutical Co., Ltd., Tokio/Tokyo Indan-derivate als thromboxan-antagonisten
CA2078758C (en) * 1991-09-27 2003-12-09 Alan M. Warshawsky 2-substituted indane-2-mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
DE69317764T2 (de) * 1992-02-14 1998-07-30 Merrell Pharmaceuticals Inc., Cincinnati, Ohio Aminoacetylmercaptoacetylamid derivate mit enkephalinase- und ace-hemmwirkung
US5484783A (en) * 1994-03-24 1996-01-16 Merrell Dow Pharmaceuticals Inc. Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic mercaptoacetylamide and benzazapine derivatives
JPH09510476A (ja) * 1994-03-24 1997-10-21 メリル・フアーマシユウテイカルズ・インコーポレイテツド 低コレステロール血性、抗アテローム性動脈硬化性および低トリグリセライド血性のアミノアセチルメルカプト誘導体
AU716519B2 (en) * 1995-06-30 2000-02-24 Laboratoires Merck Sharp & Dohme - Chibret Snc Method of treating renal disease using an ace inhibitor and an A II antagonist
EE03524B1 (et) 1995-12-27 2001-10-15 Yoshitomi Pharmaceutical Industries, Ltd. Vahend diabeedi komplikatsioonide profülaktikaks ja raviks
CA2382549C (en) * 1999-08-30 2005-03-15 Aventis Pharma Deutschland Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
US6149915A (en) 1999-09-29 2000-11-21 Shiva Biomedical, Llc Treatment of diabetic nephropathy and microalbuminuria
CZ299708B6 (cs) * 2001-04-12 2008-10-29 Sanofi - Aventis Deutschland GmbH Merkaptoacetylamidové deriváty, zpusob jejich prípravy a farmaceutické prostredky s jejich obsahem k ošetrování kardiovaskulárních onemocnení
AU2002355419A1 (en) * 2001-08-06 2003-02-24 Genomed, Llc Methods and compositions for treating diseases associated with excesses in ace

Also Published As

Publication number Publication date
HRP20041212A2 (en) 2005-06-30
DK1519732T3 (da) 2012-06-18
AU2003280440B2 (en) 2009-07-16
CN1665512A (zh) 2005-09-07
DE10229180A1 (de) 2004-01-29
MXPA04012230A (es) 2005-02-25
PA8576501A1 (es) 2004-02-07
NO334811B1 (no) 2014-06-02
CY1112905T1 (el) 2016-04-13
ECSP045513A (es) 2005-03-10
TWI326215B (en) 2010-06-21
MA27281A1 (fr) 2005-04-01
HRP20041212B1 (hr) 2013-06-30
OA12871A (en) 2006-09-15
IL165935A0 (en) 2006-01-15
CN100366254C (zh) 2008-02-06
BR0312250A (pt) 2005-04-26
TNSN04262A1 (en) 2007-03-12
JP2005533815A (ja) 2005-11-10
US20040058911A1 (en) 2004-03-25
RS52478B (en) 2013-02-28
EP1519732B1 (en) 2012-03-07
CA2490277A1 (en) 2004-01-08
SI1519732T1 (sl) 2012-05-31
SV2004001560A (es) 2004-02-26
TW200406214A (en) 2004-05-01
KR101072235B1 (ko) 2011-10-12
CR7667A (es) 2005-06-16
ZA200409382B (en) 2006-01-25
PE20040582A1 (es) 2004-10-18
CA2490277C (en) 2011-11-01
UA82845C2 (en) 2008-05-26
KR20050013642A (ko) 2005-02-04
US6930103B2 (en) 2005-08-16
ES2383889T3 (es) 2012-06-27
HN2003000193A (es) 2004-10-27
ATE548040T1 (de) 2012-03-15
AU2003280440A1 (en) 2004-01-19
PL218070B1 (pl) 2014-10-31
US7514423B2 (en) 2009-04-07
JP4564354B2 (ja) 2010-10-20
EP1519732A1 (en) 2005-04-06
NZ537480A (en) 2005-11-25
AR040343A1 (es) 2005-03-30
PL372992A1 (en) 2005-08-08
US20050171090A1 (en) 2005-08-04
UY27869A1 (es) 2003-12-31
PT1519732E (pt) 2012-05-22
IL165935A (en) 2010-12-30
WO2004002492A1 (en) 2004-01-08
RS100704A (en) 2007-02-05
RU2336080C2 (ru) 2008-10-20
HK1079435A1 (en) 2006-04-07
RU2005102087A (ru) 2005-07-10

Similar Documents

Publication Publication Date Title
WO2010036613A8 (en) Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
WO2008024390A3 (en) 2- (pyrazin-2-yl) -thiazole and 2- (1h-pyraz0l-3-yl) -thiazole derivatives as well as related compounds as stearoyl-coa desaturase (scd) inhibitors for the treatment of metabolic, cardiovascular and other disorders
NO20072608L (no) Biaryloksymetylarenkarboksylsyrer
NO20065260L (no) Tri(cyklo)substituerte amidforbindelser
JO2397B1 (en) Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
NO20084321L (no) Triazolderivat eller salt derav
EA201100097A1 (ru) Производные пиразоло[3,4]пиримидин-4-ила и их применения для лечения диабета и ожирения
SG155961A1 (en) Pyrazoles as 11-beta-hsd-1
TNSN08533A1 (en) Modulators of metabolism and the treatment of disorders related thereto
ATE419848T1 (de) Cycloalkyl-lactam-derivate als inhibitoren von 11-beta-hydroxysteroiddehydrogenase 1
ATE472531T1 (de) Sulfonylverbindungen als hemmer von 11-beta- hydroxysteroiddehydrogenase-1
NO20090064L (no) Pyrasoler som glucokinase aktivatorer
IL186566A0 (en) Substituted 2-amin0alkylth10-benzimidaz0les and use thereof for reducing blood sugar levels
NO20056010L (no) Biaryloksymetylaren-karboksylsyrer
SG151271A1 (en) Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof
EP1638947A4 (en) TRIAZONE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1
UA94741C2 (en) Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
MX2009012390A (es) Uso de compuestos de 4-(pirrolidin-1-il)quinolina para exterminar microorganismos clinicamente latentes.
NO20082496L (no) Pyrazinderivater
EA200501645A1 (ru) Ингибиторы гликогенфосфорилазы, представляющие собой амиды пирролопиридин-2-карбоновых кислот
WO2007145835A3 (en) Benzamide derivatives as modulators of 11beta-hsd1 for treating diabetes and obesity
WO2006058628A3 (en) Substituted benzoquinolizines as dpp-iv inhibitors for the treatment of diabetes
TW200407133A (en) Novel PPARα and PPARγ agonists
ATE515494T1 (de) Neue verbindungen, deren herstellung und verwendung

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees